businessbriefs
10:49in productionCh. 1 · The Merger/ 10:49 · ceiling 15 min
Companies

Daiichi Sankyo

2005

A merger-born giant that bought its way into oncology — but still answers to US prosecutors for kickbacks.

Daiichi Sankyo is a post-merger pharmaceutical entity whose scale derives from consolidation — not innovation velocity. Its revenue is large, its global reach documented, but its growth levers are acquisitions and inherited assets. Its 2015 $39 million kickback settlement signals real regulatory exposure — not just theoretical compliance risk.

CompaniesPhotographyMedicineGlobalisationPhotography across the network →
Chapters & takeaways6
  1. 0:59
    The Merger

    Daiichi Sankyo did not grow organically — it was created in 2005 by merging two century-old Japanese firms.

  2. 2:16
    Scale and Standing

    It is Japan’s second-largest pharma firm and holds formal status in Europe and global industry bodies.

  3. 3:13
    How It Entered the US

    Revenue is reported at scale, but its US operations and commercial expansion began only in 2006 — via acquisition, not launch.

  4. 4:27
    Legacy Assets

    Its lineage includes foundational science — adrenaline isolation — and early global moves like the 1990 Munich acquisition.

  5. 5:50
    First Acquisition

    Its first US move was buying Zepharma — an OTC unit — not a novel drug or platform.

  6. 7:14
    Time Between Birth and Scale

    The 2005 merger set the stage, but the 2022 revenue figure reflects 17 years of consolidation — not the merger’s immediate output.

Worth your time?

Yes. Study the whole thing.

3.5/ 5
What works
  • merger execution
  • international institutional alignment (EFPIA/IFPMA)
  • acquisition sequencing in oncology
What does not
  • claim profitability
  • disclose R&D spend
  • state number of employees
  • identify key products or patents beyond adrenaline
Study it if
  • analysts tracking pharma M&A
  • regulatory watchers
  • Japan-based industrial historians
Skip it if
  • startups seeking innovation playbooks
  • investors assessing unit economics
The written brief1 min read

What the company or idea is

Daiichi Sankyo is a global pharmaceutical company formed in 2005 by merging two century-old Japanese firms: Sankyo Company, Limited and Daiichi Pharmaceutical Company, Limited.

How it actually makes money

Daiichi Sankyo makes money from selling pharmaceuticals globally, with JPY 1,278 billion in revenue in 2022.

What works

Its merger created Japan’s second-largest pharmaceutical company. Its international presence is verified via subsidiaries and membership in EFPIA and IFPMA. Its US entry in 2006 and subsequent oncology-focused acquisitions signal deliberate geographic and therapeutic repositioning.

What does not

It does not operate in the US as of 2005; its US subsidiary began in 2006. It does not claim or demonstrate profitability, margins, or R&D spend — only revenue and acquisition activity.

What to take from it

The gap between its self-presentation as a global innovator and its documented reliance on acquisitions (Zepharma, U3 Pharma, Plexxikon, Ambit Biosciences) and legacy assets (e.g., Luitpold-Werk, acquired in 1990 by Sankyo) reveals a strategy built more on consolidation than organic pipeline creation.

Is it worth your time

Yes — as a case study in post-merger portfolio expansion through targeted acquisitions and regulatory risk exposure in the US market.

Same desk · Companies4 of 164
10:56
ABBCharles Eugene Lancelot Brown · 1988ABB is a post-merger industrial incumbent whose value lies in proven, regulated, physical infrastructure — not software, platforms, or scalability stories.
10:50
AbbVie2012AbbVie is a textbook example of post-innovation pharmaceutical value extraction — built on a single blockbuster, sustained by patent thickets and pricing, checked only by biosimilars and congressional scrutiny.
10:55
Air Canada1937Air Canada is Canada’s state-founded, privatised, hub-based flag carrier—large by fleet and passengers, anchored in Montreal, Toronto, and Vancouver, and embedded in Star Alliance. It carried 45.3 million passengers in 2025. It was founded in 1937 as Trans-Canada Air Lines, renamed in 1965, privatised in 1988, acquired Canadian Airlines in 2000, and filed for bankruptcy protection in 2003 before emerging in 2004.
10:34
Air France1933Air France is the French flag carrier, formed on 30 August 1933 via merger of five airlines. It operates from Charles de Gaulle Airport, served 201 destinations across 78 countries as of 2013, and held a politically critical role in West Berlin from 1950 to 1990. Since 2003, it has been a subsidiary of Air France–KLM — not an independent entity. Its revenue comes from scheduled passenger and cargo services. Its longevity reflects state support and geopolitical utility, not market resilience or innovation.
Up next in Business

De Beers

Cecil Rhodes · 1888 · 10:51

De Beers wasn’t a diamond company — it was a scarcity engine.

Play nextBack to Companies
10:51